myelodysplastic syndromes/feber

Länken sparas på Urklipp

Välj sorteringstyp

Sida 1 från 401 resultat

Fever--a manifestation of preleukemia.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

A patient had a preleukemic syndrome in which the major manifestation was a chronic relapsing fever over an 18-month period. A review of the literature shows that fever may be present in a considerable number of patients with preleukemia.

Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

The DNA hypomethylating agent azacitidine was approved by the United States Food and Drug Administration after the drug demonstrated superiority over the best supportive care for treatment of myelodysplastic syndrome in patients unable to undergo stem cell transplantation. Mild adverse reactions,

Presentation of familial Mediterranean fever in a heterozygous MEFV mutation triggered by immunosuppressive therapy for myelodysplastic syndrome.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Familial Mediterranean fever (FMF) is a recessively inherited disease characterized by recurrent episodes of systemic inflammation. The cause of this disease is the mutations affecting both the alleles of MEFV gene. We describe here a case in a heterozygous MEFV mutation complicated with

Sweet's syndrome associated with recurrent fever in a patient with trisomy 8 myelodysplastic syndrome.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

In the case of a 69-year-old man suffering from recurrent high fever, laboratory data demonstrated elevated inflammatory findings such as neutrophilic leukocytosis and an increase in serum level of C-reactive protein. A nonsteroidal antiinflammatory drug or a low dose of prednisolone proved to be

Connecting the Dots From Fever of Unknown Origin to Myelodysplastic Syndrome: GATA2 Haploinsufficiency.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Leukemia-predisposing conditions, such as GATA2 haploinsufficiency, are known for their high penetrance and expressivity profiles. These disorders pose a difficult diagnostic challenge to even the most experienced clinician when they first present. We describe the case of a 17-year-old male

Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Fever represents the major surrogate of infection in neutropenic cancer patients. A number of neutropenic fever syndromes have been recognized, the causes and significance of which will vary depending upon the clinical context. First neutropenic fever syndromes are typically of bacterial origin, the

Acute brucellosis with myelodysplastic syndrome presenting as pancytopenia and Fever of unknown origin.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE To report a rare case of brucellosis with myelo-dysplastic syndrome (MDS). METHODS A 70-year-old woman presented with pancytopenia and fever of unknown origin (FUO). The initial diagnosis was brucellosis; the woman was treated with doxycycline and rifampin against Brucella melitensis but

[Soft tissue tumor and fever in a patient with myelodysplastic syndrome].

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Medical Treatment of Postendoscopic Submucosal Dissection Phlegmonous Gastritis in an Elderly Diabetic Woman with Myelodysplastic Syndrome.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Phlegmonous gastritis is a rare, suppurative disease characterized by full-thickness exudative changes, infiltration of inflammatory cells, and edema primarily in the submucosal layer. A 76-year-old woman with type 2 diabetes and myelodysplastic syndrome underwent endoscopic submucosal dissection

Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

In a phase I-II study, nine patients with myelodysplastic syndromes and concomitant severe transfusion-dependent cytopenias were treated with recombinant human interleukin-3 (rhIL-3) to improve hematopoietic function. Doses of rhIL-3 ranged from 250 micrograms/m2 to 500 micrograms/m2 and were given

A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

We performed a phase I/II study of recombinant human interleukin-3 (rhIL-3) in 21 patients with aplastic anemia (AA) or myelodysplasia (MDS). Patients received 21-day cycles of IL-3 (0.5, 1.25, 2.5, 5.0, or 10 micrograms/kg/d) by subcutaneous injection followed by a 10- to 14-day washout period.

Case of Sweet's syndrome with extensive necrosis and ulcers accompanied by myelodysplastic syndrome.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

A 43-year-old woman presented with a persistent high fever of 39 degrees C and edematous erythema accompanied by pustules on the face, trunk and extremities. Conjunctivitis and nodules were also observed in the right eye. On the basis of the clinical symptoms and histopathological findings. Sweet's

Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Symptomatic patients with myelodysplastic syndromes (MDS) and 10-30% blasts in the bone marrow were treated with low-dose AraC (2 x 10 mg/m2 subcutaneously (sc) days 1-14) and GM-CSF (fully glycosylated, Sandoz/Schering-Plough, 2 x 150 micrograms protein/day sc) given either subsequently (days

[Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

From 1998 to 2001, 5 consecutive cases of AML/TMDS entered our hospital and achieved complete remission (CR) with continuous drip infusion of low-dose etoposide and low-dose Ara-C combined with mitoxantrone (MEtA regimen). The ages of the 5 patients (4 males and 1 female) ranged 32 to 50 years-old,

A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

In a randomized phase II study, patients with myelodysplastic syndromes (MDS) with 10-30% blasts in the bone marrow and hematopoietic failure were treated with low-dose Ara C (2 x 10 mg/m2 subcutaneously (s.c.) days 1-14) and rhGM-CSF (fully glycosylated, Sandoz/Schering-Plough, 2 x 150 micrograms

Tidigare
1
2
3
4
5
6
...
26
27
Nästa

Gå med på vår
facebook-sida

Herbal & Natural Medicine

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

Fungerar på 55 språk
Växtbaserade botemedel som stöds av vetenskap
Örter igenkänning av bild
Interaktiv GPS-karta - märka örter på plats (kommer snart)
Läs vetenskapliga publikationer relaterade till din sökning
Sök efter medicinska örter efter deras effekter
Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning